EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phage display identification of MCR-1-targeting nanobodies to restore colistin susceptibility

Yajie Zhao, Li Zhang, Lanjie Ren, Chenyu Lou, Xu Zhang, Manping Gu, Liang Zhao, Suxia Wu iD, Qiming Li iD

Microbiology Spectrum · 18.11.2026

DOI: 10.1128/spectrum.01904-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, online erschienen am 18.11.2026. Verfasst von Yajie Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Henan Province EngineeringTechnology Research Center of Rapid-Accuracy Medical Diagnostics, Department of Clinical Laboratory, The First Affiliated H…. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Provinces and ministries jointly build key projects of henan provincial health commission, Provinces and Ministries jointly youth project of henan provincial health commission, the National science foundation of henan province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The spread of antimicrobial resistance among gram-negative bacilli, particularly within Enterobacteriaceae and non-fermentative gram-negative bacilli, poses a serious and escalating threat to global public health. Colistin, a cationic antimicrobial peptide, remains a last-line treatment for infections caused by multidrug-resistant gram-negative bacteria. However, the global dissemination of the plasmid-encoded colistin resistance gene mobilized colistin resistance-1 ( mcr-1 ) has contributed to increasing cases of colistin resistance and threatens global health. Nanobodies offer advantages, including high affinity, stability, and small size. Here, we isolated anti-MCR-1.1 nanobodies from a phage-display library and evaluated their potential to restore colistin efficacy. The periplasmic catalytic domain of MCR-1.1 was purified by affinity chromatography and used to immunize alpacas, resulting in the construction of a phage-displayed nanobody library against MCR-1.1 with a size of 5.8 × 10⁸ CFU. After biopanning, several anti-MCR-1.1 nanobodies specific for the periplasmic catalytic domain of MCR-1.1 were successfully isolated. Among them, high-affinity nanobodies Nb7, Nb12, Nb24, and Nb30 were selected in vitro , with Nb30 demonstrating promising activity. Following engineering, the Nb30-1 variant was generated and shown to exhibit enhanced efficacy. In combination with colistin, Nb30-1 effectively inhibited the growth of colistin-resistant, MCR-1.1-expressing laboratory Escherichia coli BL21(DE3), as determined by the growth dynamics curve. Molecular docking analysis revealed the binding interactions between Nb30/Nb30-1 and the MCR-1.1 protein, and affinity measurements confirmed their high binding affinity for the MCR-1.1 antigen. Given the exquisite conservation of key catalytic residues and the epitope recognized by Nb30-1 across MCR-1 variants, Nb30-1 represents a promising macromolecular adjuvant strategy to overcome MCR-1-mediated resistance. IMPORTANCE The escalating use of antibiotics has driven a global rise in antibiotic resistance, underscoring an urgent need for adjuvants that can restore the susceptibility of drug-resistant bacteria. In this study, we isolate anti-MCR-1 nanobodies from a phage-display library and evaluate their potential to restore colistin efficacy. Following engineering, the Nb30-1 variant was generated and shown to exhibit enhanced efficacy. These findings suggest that engineered anti-MCR-1 nanobodies, particularly Nb30-1, represent a promising therapeutic strategy to combat MCR-1-positive colistin-resistant bacterial infections by resensitizing bacteria to colistin.

Schlagwörter

Stichwörter der Autor:innen

MCR-1colistincombinatorial therapynanobodiesphage display

Autor:innen und Institutionen

  • Henan Province EngineeringTechnology Research Center of Rapid-Accuracy Medical Diagnostics, Department of Clinical Laboratory, The First Affiliated Hospital of Henan University, Henan University, Kaifeng, China.
  • The Jointed National Laboratory of Antibody Drug Engineering, Henan University, Kaifeng, China.
  • State Key Laboratory of Antiviral Drugs, Henan University, Kaifeng, China.

ORCID-Profile: Suxia Wu, Qiming Li

Förderung

  • Provinces and ministries jointly build key projects of henan provincial health commission
  • Provinces and Ministries jointly youth project of henan provincial health commission
  • the National science foundation of henan province
  • Henan province key research and development and promotion project
  • the platform construction fund of Henan province Engineering Technology Research Center of Rapid-Accuracy Medical Diagnostics
  • Henan province Higher Education Key Scientific Research Project Plan

Zitieren

APA

Zhao, Y., Zhang, L., Ren, L., Lou, C., Zhang, X., Gu, M., Zhao, L., Wu, S., & Li, Q. (2026). Phage display identification of MCR-1-targeting nanobodies to restore colistin susceptibility. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01904-26

Vancouver

Zhao Y, Zhang L, Ren L, Lou C, Zhang X, Gu M, et al. Phage display identification of MCR-1-targeting nanobodies to restore colistin susceptibility. Microbiology Spectrum. 2026. doi:10.1128/spectrum.01904-26

BibTeX
@article{Zhao2026,
  author = {Zhao, Yajie and Zhang, Li and Ren, Lanjie and Lou, Chenyu and Zhang, Xu and Gu, Manping and Zhao, Liang and Wu, Suxia and Li, Qiming},
  title = {Phage display identification of MCR-1-targeting nanobodies to restore colistin susceptibility},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.01904-26}
}
Kostenlos starten →